POSTERS & PUBLICATIONS
From the latest randomized trials and methodologies to solid research results, find all the information you need. Click on any media below to download.
POSTERS
San Antonio Breast Cancer (SABCS) Annual Symposium 2020
12.2020
San Antonio Breast Cancer (SABCS) Annual Symposium 2020
Differential efficacy of pegfilgrastim (Peg) in patients (pts) with breast cancer (BC) versus other cancer types for the prevention of docetaxel (Doc) chemotherapy-induced neutropenia (CIN).
San Antonio Breast Cancer (SABCS) Annual Symposium 2020
12.2020
Annual San Antonio Breast Cancer Symposium 2020
Plinabulin and pegfilgrastim versus pegfilgastrim monotherapy after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain.
San Antonio Breast Cancer (SABCS) Annual Symposium 2020
12.2020
Annual San Antonio Breast Cancer Symposium
Protective 2 (BPI 2358 106): a Confirmatory Trial to Demonstrate Superiority of the Plinabulin (Plin) + Pegfilgrastim (Peg) Comb ination versus Standard of Care Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia in Breast Cancer Patients.
European Society for Medical Oncology (ESMO) Congress (2020)
09.2020
European Society for Medical Oncology (ESMO) Virtual Congress 2020
Plinabulin is a more Favorable Option for the Prevention of Chemotherapy Induced Neutropenia (CIN) than Pegfilgrastimduring the COVID-19 Pandemic.
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Severe Neutropenia (Grade 4 Neutropenia) as a Population Based Predictor for Adverse Clinical Outcome of Chemotherapy Induced Neutropenia
European Society for Medical Oncology (ESMO) Congress (2021)
09.2021
European Society for Medical Oncology (ESMO) Congress (2021)
Impact of Adding Plinabulin to Pegfilgrastim for the Prevention of Chemotherapy Induced Neutropenia on Patient Quality of Life (QoL)
PUBLICATIONS
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Clinical Cancer Research (2010) 16:5892-5899
12.01.2010
Clinical Cancer Research (2010) 16:5892-5899
Phase 1 First-in-Human Trial of the Vascular Disrupting Agent Plinabulin (NPI-2358) in Patients with Solid Tumors or Lymphomas
Blood 2011
03.2011
Blood
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells